Recovery Peptide Safety (BPC-157, TB-500)
Safety considerations for unapproved recovery peptides BPC-157 and TB-500. Learn why these peptides carry unknown risks and what the evidence limitations mean for safety.
Safety Overview
BPC-157 and TB-500 are not approved by any regulatory agency. Their safety in humans is not established.
What We Don’t Know
| Unknown | Concern |
|---|---|
| Human pharmacokinetics | How it’s absorbed, distributed, metabolized |
| Effective dosing | No established safe/effective range |
| Long-term effects | No chronic exposure studies |
| Drug interactions | Not studied |
| Contraindications | Not established |
Theoretical Concerns
BPC-157
- Pro-angiogenic effects (blood vessel growth)
- Theoretical concern for cancer progression
- Unknown effects on existing conditions
TB-500
- Related to wound healing pathways
- Effects on tumor growth unknown
- Cardiovascular effects not characterized
Product Quality Risks
Products sold online may have:
- No quality verification
- Unknown purity
- Bacterial contamination
- Incorrect peptide content
- Degradation
WADA Status
Both BPC-157 and TB-500 are prohibited by WADA in competitive sports.
The Evidence Problem
- Most research is in animals
- BPC-157 studies mostly from one research group
- TB-500 data extrapolated from parent compound
- No Phase 3 trials exist
Recommendation
Given the lack of safety data, consider:
- Evidence-based treatments for injuries
- Consultation with sports medicine physicians
- Physical therapy and proven rehabilitation methods
These peptides are not FDA-approved. Safety is unknown. This is for educational purposes only.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.